Psychedelic clinical trials are often unblinded because participants can tell when they received an active compound, which can bias outcomes. Dr. Joshua Woolley and colleagues propose UMBRAA — a multidrug active-placebo combined with limited, authorized disclosure — to better mimic psychedelic sessions and reduce expectancy effects. A JAMA Psychiatry analysis found within-group improvements in open-label SSRI studies similar to psilocybin trials, raising concerns about current masking. The authors call for careful safety testing and empirical trials to validate the approach.
Are Psychedelic Trials Overstating Benefits? Researchers Propose a Multidrug Fix (UMBRAA)
psychedelic clinical trials
Clinical trials of psychedelic therapies face a persistent methodological problem: participants frequently know whether they received the active drug, and that unblinding can bias results. Researchers led by Dr. Joshua Woolley (UCSF) argue that better control conditions and trial procedures are needed to determine whether reported benefits come from the drugs’ pharmacology or from the powerful subjective experience they produce.
Why Blinding Matters
In many psychedelic studies, more than 90% of participants correctly identify that they received the active compound. When subjects can tell which arm they are in, expectation effects and altered placebo responses can skew outcomes. Woolley notes that placebo responses in psychedelic trials are roughly half those seen in SSRI and ketamine studies — a discrepancy that complicates comparisons and may inflate apparent efficacy for psychedelics.
The Evidence So Far
A JAMA Psychiatry analysis that compared psychedelic trials with open-label antidepressant trials found that within-group improvements (how much patients improved after treatment without a randomized control) were similar between open-label SSRI studies and psilocybin trials. That result prompted questions among researchers: are the striking acute effects reported in many psilocybin trials a consequence of the treatment itself, or of trial design and expectation?
“Niacin has been tried … Either people met God or they got itchy,”
— Dr. Joshua Woolley, describing past attempts to mask psychedelic effects in control groups.
Proposed Fix: UMBRAA
In a JAMA Psychiatry viewpoint, Woolley and colleagues propose a novel approach called UMBRAA (Unidentifiable Multidrug Blinding With Reduced, Authorized Awareness). Instead of inert placebos or low-dose comparators that participants easily distinguish from full psychedelic doses, UMBRAA would use a tailored cocktail of active agents (for example, combinations drawn from stimulants, sedatives, anticholinergics and cannabinoids) designed to mimic the acute perceptual and physiological profile of a psychedelic session while remaining distinct pharmacologically.
The proposal also recommends limited, authorized disclosure of certain trial details so participants cannot reliably deduce their assignment, while being informed that some procedural information will be withheld and why. The authors emphasize safety: multidrug controls would need careful, stepwise development starting with conservative doses and robust monitoring.
Tradeoffs, Ethics and Practical Implications
Active multidrug placebos raise ethical and safety questions that must be addressed through rigorous development and oversight. Opponents may point to precedent for challenging blinding in other fields — for instance, sham surgical controls — but multidrug controls require thorough preclinical and early-phase testing to avoid harm or confounding pharmacology (some comparators, like dextromethorphan, have antidepressant properties themselves).
Getting trial design right matters practically: psychedelic treatments can be resource intensive and costly, involving long clinic sessions and therapy support. Overestimating benefits could divert patients and resources away from effective alternatives.
Where the Field Is Headed
Investment and clinical progress continue: Compass Pathways’ COMP360 (psilocybin for treatment-resistant depression) posted positive phase 3 results and expects to file with the FDA, and Eli Lilly recently completed a multibillion-dollar acquisition that expands its psychedelic pipeline. Meanwhile, Woolley’s team plans empirical studies to test limited-disclosure procedures and multidrug placebos and is seeking federal funding to support this work.
Bottom line: UMBRAA and similar strategies aim to produce more rigorous, trustworthy evidence about whether psychedelics’ clinical effects derive from their pharmacology, their subjective acute experiences, or a mix of both. Careful, transparent development and ethical oversight will be essential if the field adopts these methods.
Help us improve.
